Olema Pharmaceuticals (OLMA) Receivables - Other (2021 - 2026)

Olema Pharmaceuticals (OLMA) has 6 years of Receivables - Other data on file, last reported at $3.3 million in Q1 2026.

• Receivables - Other for Q1 2026 came in at $3.3 million, up 72.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 million (up 72.97% YoY), and the FY2025 annual result was $3.1 million, up 47.97% from the prior year.
• Receivables - Other rose to $3.3 million in Q1 2026 per OLMA's latest filing, from $3.1 million in the prior quarter.
• Over five years, Receivables - Other peaked at $3.3 million in Q1 2026 and troughed at $221000.0 in Q2 2023.
• A 5-year average of $1.3 million and a median of $687000.0 in 2024 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2023 and 2024: Receivables - Other dropped 8.32% in 2023, then soared 271.49% in 2024.
• A 5-year view of Receivables - Other shows it stood at $319000.0 in 2022, then jumped by 110.97% to $673000.0 in 2023, then soared by 215.01% to $2.1 million in 2024, then jumped by 47.97% to $3.1 million in 2025, then grew by 5.87% to $3.3 million in 2026.
• Business Quant data shows OLMA's Receivables - Other at $3.3 million in Q1 2026, $3.1 million in Q4 2025, and $2.1 million in Q3 2025.